Tag: Prolifagen Therapeutics

Prolifagen Therapeutics Appoints M. Alexander Shaw, PhD, as Chief Executive Officer

VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ — Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In this role, Dr. Shaw will lead Prolifagen’s efforts in bringing new medicines to market to prevent development of heart failure in patients with large myocardial […]